'In the second quarter of 2019, Allergan delivered steady growth in our key products including BOTOX, VRAYLAR, JUVEDERM, Lo
LOESTRIN and OZURDEX while we continued to advance our pipeline, highlighted by the FDA's approval of VRAYLAR(Cariprazine) for Bipolar Depression and the NDA acceptance for Bimatoprost SR for Glaucoma,' said Brent Saunders, Chairman and CEO of Allergan.
"In the second quarter of 2019, Allergan delivered steady growth in our key products including Botox, Vraylar, Juvederm, Lo
Loestrin, and Ozurdex,vwhile we continued to advance our pipeline, highlighted by the FDA's approval of VRAYLAR (Cariprazine) for Bipolar Depression and the NDA acceptance for Bimatoprost SR for Glaucoma," said Brent Saunders, CEO of Allergan.
General Medicine revenues were $1.3 billion, up 2%, primarily due to growth in VRAYLAR and Lo
LOESTRIN, partially offset by lower revenues from products that lost exclusivity.
Growth of key products such as BOTOX Cosmetic, BOTOX Therapeutic, VRAYLAR, JUVEDERM and Lo
LOESTRIN offset declines in products that lost exclusivity and products which were divested in 2018," said Brent Saunders, Chairman and CEO of Allergan.
Loestrin 24 FE Antitrust Litig.), 814 F.3d 538, 549-53 (1st Cir.
In re
Loestrin 24 Fe Antitrust Litig., 814 F.3d 538, 552 (1st Cir.
Recent generic launches include diclofenac topical solution, 1.5% (Pennsaid 1.5%); norgestimate and ethinyl estradiol tablets (Ortho Tri-Cyclen); Blisovi Fe 1.5/30 tablets (
Loestrin Fe 1.5/30); Blisovi Fe 1/20 tablets (
Loestrin Fe 1/20); and zolpidem tartrate sublingual, CIV tablets (Intermezzo).
See, e.g., In re
Loestrin 24 FE Antitrust Litig., 45 F.
The continuous oral contraceptive was ethinyl estradiol 10 mcg/norethindrone acetate 1 mg under the brand name
LoEstrin 1/20.
M2 EQUITYBITES-November 6, 2014-Mylan reports market availability of generic
Loestrin 24 Fe for contraception
M2 PHARMA-November 6, 2014-Mylan reports market availability of generic
Loestrin 24 Fe for contraception